Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results
"The third quarter of 2017 was highlighted by the approval and strong launch of Vyxeos in the U.S. for the treatment of adult patients with newly-diagnosed high-risk AML, leading to our increase in 2017 Vyxeos sales guidance," said
GAAP net income for the third quarter of 2017 was
Adjusted net income for the third quarter of 2017 was
The tax provision and the effective tax rate for the third quarter of 2017 on both a GAAP and non-GAAP basis were favorably impacted by certain tax benefits. For further information, see "Operating Expenses and Income Tax Provision" below. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Financial Highlights
Three Months Ended |
Nine Months Ended |
||||||||||||||||||||
(In thousands, except per share amounts and percentages) |
2017 |
2016 |
Change |
2017 |
2016 |
Change |
|||||||||||||||
Total revenues |
$ |
411,855 |
$ |
374,181 |
10 |
% |
$ |
1,182,294 |
$ |
1,091,352 |
8 |
% |
|||||||||
GAAP net income |
$ |
63,526 |
$ |
89,828 |
(29) |
% |
$ |
255,641 |
$ |
280,142 |
(9) |
% |
|||||||||
Adjusted net income |
$ |
197,649 |
$ |
161,153 |
23 |
% |
$ |
496,225 |
$ |
461,525 |
8 |
% |
|||||||||
GAAP EPS |
$ |
1.03 |
$ |
1.45 |
(29) |
% |
$ |
4.17 |
$ |
4.51 |
(8) |
% |
|||||||||
Adjusted EPS |
$ |
3.22 |
$ |
2.61 |
23 |
% |
$ |
8.09 |
$ |
7.43 |
9 |
% |
Total Revenues
Three Months Ended |
Nine Months Ended |
||||||||||||||
(In thousands) |
2017 |
2016 |
2017 |
2016 |
|||||||||||
Xyrem® (sodium oxybate) oral solution |
$ |
303,870 |
$ |
285,907 |
$ |
874,222 |
$ |
816,412 |
|||||||
Erwinaze® / Erwinase® (asparaginase Erwinia chrysanthemi) |
49,173 |
42,986 |
149,585 |
143,907 |
|||||||||||
Defitelio® (defibrotide sodium) / defibrotide |
31,213 |
28,137 |
97,351 |
79,280 |
|||||||||||
VyxeosTM (daunorubicin and cytarabine) liposome for injection |
9,719 |
— |
9,719 |
— |
|||||||||||
Prialt® (ziconotide) intrathecal infusion |
7,930 |
8,783 |
21,303 |
23,065 |
|||||||||||
Other |
6,066 |
5,808 |
19,124 |
21,983 |
|||||||||||
Product sales, net |
407,971 |
371,621 |
1,171,304 |
1,084,647 |
|||||||||||
Royalties and contract revenues |
3,884 |
2,560 |
10,990 |
6,705 |
|||||||||||
Total revenues |
$ |
411,855 |
$ |
374,181 |
$ |
1,182,294 |
$ |
1,091,352 |
Net product sales increased 10% in the third quarter of 2017 compared to the same period in 2016 primarily due to an increase in net product sales of our lead marketed products.
Xyrem net product sales increased 6% in the third quarter of 2017 compared to the same period in 2016. Xyrem net product sales growth in the 2017 period was negatively impacted by payer mix, one fewer shipping day, and operational changes that delayed some prescription fulfillment.
Erwinaze/Erwinase net product sales increased 14% in the third quarter of 2017 compared to the same period in 2016. The company experienced supply disruptions during both periods; however, net product sales were higher in the third quarter of 2017 compared to the same period in 2016 due to the timing of product availability. The company expects that additional supply disruptions may occur in 2017 and into 2018.
Defitelio/defibrotide net product sales increased 11% in the third quarter of 2017 compared to the same period in 2016 primarily due to an increase in U.S. net product sales. The company expects continued inter-quarter variability in Defitelio net sales given that veno-occlusive disease is an ultra-rare disease.
Vyxeos net product sales in the third quarter of 2017 were
Operating Expenses and Income Tax Provision
Three Months Ended |
Nine Months Ended |
||||||||||||||
(In thousands, except percentages) |
2017 |
2016 |
2017 |
2016 |
|||||||||||
GAAP: |
|||||||||||||||
Cost of product sales |
$ |
31,203 |
$ |
24,311 |
$ |
84,940 |
$ |
71,730 |
|||||||
Gross margin |
92.4 |
% |
93.5 |
% |
92.7 |
% |
93.4 |
% |
|||||||
Selling, general and administrative |
$ |
124,523 |
$ |
124,368 |
$ |
401,106 |
$ |
375,751 |
|||||||
% of total revenues |
30.2 |
% |
33.2 |
% |
33.9 |
% |
34.4 |
% |
|||||||
Research and development |
$ |
47,362 |
$ |
47,796 |
$ |
132,447 |
$ |
118,139 |
|||||||
% of total revenues |
11.5 |
% |
12.8 |
% |
11.2 |
% |
10.8 |
% |
|||||||
Acquired in-process research and development |
$ |
75,000 |
$ |
15,000 |
$ |
77,000 |
$ |
23,750 |
|||||||
Income tax provision |
$ |
1,239 |
$ |
26,437 |
$ |
65,914 |
$ |
100,888 |
|||||||
Effective tax rate |
1.9 |
% |
22.7 |
% |
20.5 |
% |
26.5 |
% |
|||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
(In thousands, except percentages) |
2017 |
2016 |
2017 |
2016 |
|||||||||||
Non-GAAP adjusted: |
|||||||||||||||
Cost of product sales |
$ |
29,630 |
$ |
22,963 |
$ |
80,594 |
$ |
68,620 |
|||||||
Gross margin |
92.7 |
% |
93.8 |
% |
93.1 |
% |
93.7 |
% |
|||||||
Selling, general and administrative |
$ |
103,620 |
$ |
94,534 |
$ |
333,524 |
$ |
296,633 |
|||||||
% of total revenues |
25.2 |
% |
25.3 |
% |
28.2 |
% |
27.2 |
% |
|||||||
Research and development |
$ |
42,712 |
$ |
43,323 |
$ |
118,796 |
$ |
106,847 |
|||||||
% of total revenues |
10.4 |
% |
11.6 |
% |
10.0 |
% |
9.8 |
% |
|||||||
Income tax provision |
$ |
24,410 |
$ |
38,500 |
$ |
104,307 |
$ |
129,663 |
|||||||
Effective tax rate |
11.0 |
% |
19.3 |
% |
17.4 |
% |
21.9 |
% |
Operating expenses changed over the prior year period primarily due to the following:
- Selling, general and administrative (SG&A) expenses increased in the third quarter of 2017 compared to the same period in 2016 on a GAAP and on a non-GAAP adjusted basis due to higher headcount and other expenses resulting from the expansion of the company's business, including the launch of Vyxeos in the U.S. SG&A expenses in the third quarter of 2016 on a GAAP basis included transaction and integration costs of
$10.3 million . - Research and development (R&D) expenses were consistent on a GAAP and on a non-GAAP adjusted basis in the third quarter of 2017 compared to the same period in 2016. R&D expenses in the third quarter of 2017 reflected an increase in expenses related to the company's ongoing clinical development programs and regulatory activities, including an increase in headcount, and a decrease in JZP-110 costs following the completion of three Phase 3 studies this year.
The tax provision and the effective tax rate for the third quarter of 2017 on both a GAAP and non-GAAP basis were favorably impacted by the release of a valuation allowance held against certain foreign net operating losses and the release of reserves related to uncertain tax positions upon the expiration of a statute of limitation.
Cash Flow and Balance Sheet
As of September 30, 2017, cash, cash equivalents and investments were
Recent Developments
- In
August 2017 , the company andImmunoGen, Inc. entered into a collaboration and option agreement granting the company rights to opt into exclusive, worldwide licenses to develop and commercialize two early-stage, hematology-related antibody-drug conjugate (ADC) programs, as well as an additional program to be designated during the term of the agreement. The programs covered under the agreement include IMGN779, a CD33-targeted ADC for the treatment of acute myeloid leukemia (AML) in Phase 1 testing, and IMGN632, a CD123-targeted ADC for hematological malignancies expected to enter clinical testing before the end of the year. - In
November 2017 , the company submitted a Marketing Authorization Application (MAA) for Vyxeos to theEuropean Medicines Authority (EMA) for the treatment of high-risk AML patients. Separately, the EMA granted Vyxeos an accelerated assessment review and theUK Medicines and Healthcare Products Regulatory Agency granted Vyxeos the Promising Innovative Medicine designation.
2017 Financial Guidance
Revenues |
$1,600-$1,650 |
Total net product sales |
$1,590-$1,630 |
-Xyrem net sales |
$1,180-$1,200 |
-Erwinaze/Erwinase net sales |
$200-$215 |
-Defitelio/defibrotide net sales |
$130-$150 |
-Vyxeos net sales |
$20-$30 |
GAAP gross margin % |
93% |
Non-GAAP adjusted gross margin %1,4 |
93% |
GAAP SG&A expenses |
$521-$551 |
Non-GAAP adjusted SG&A expenses2,4 |
$440-$460 |
GAAP R&D expenses |
$180-$200 |
Non-GAAP adjusted R&D expenses3,4 |
$165-$180 |
GAAP net income per diluted share |
$5.30-$6.30 |
Non-GAAP adjusted net income per diluted share4 |
$10.70-$11.20 |
1. |
Excludes $5 million of share-based compensation expense from estimated GAAP gross margin. |
||
2. |
Excludes $75-$85 million of share-based compensation expense and $6 million of expenses related to certain legal proceedings and restructuring from estimated GAAP SG&A expenses. |
||
3. |
Excludes $15-$20 million of share-based compensation expense from estimated GAAP R&D expenses. |
||
4. |
See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the table titled "Reconciliation of GAAP to Non-GAAP Adjusted 2017 Net Income Guidance" at the end of this press release. |
Conference Call Details
A replay of the conference call will be available through
About
Non-GAAP Financial Measures
To supplement
The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
|||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||
(Unaudited) |
|||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
2017 |
2016 |
2017 |
2016 |
||||||||||||
Revenues: |
|||||||||||||||
Product sales, net |
$ |
407,971 |
$ |
371,621 |
$ |
1,171,304 |
$ |
1,084,647 |
|||||||
Royalties and contract revenues |
3,884 |
2,560 |
10,990 |
6,705 |
|||||||||||
Total revenues |
411,855 |
374,181 |
1,182,294 |
1,091,352 |
|||||||||||
Operating expenses: |
|||||||||||||||
Cost of product sales (excluding amortization of intangible assets) |
31,203 |
24,311 |
84,940 |
71,730 |
|||||||||||
Selling, general and administrative |
124,523 |
124,368 |
401,106 |
375,751 |
|||||||||||
Research and development |
47,362 |
47,796 |
132,447 |
118,139 |
|||||||||||
Acquired in-process research and development |
75,000 |
15,000 |
77,000 |
23,750 |
|||||||||||
Intangible asset amortization |
47,313 |
26,453 |
99,164 |
75,832 |
|||||||||||
Total operating expenses |
325,401 |
237,928 |
794,657 |
665,202 |
|||||||||||
Income from operations |
86,454 |
136,253 |
387,637 |
426,150 |
|||||||||||
Interest expense, net |
(19,192) |
(18,498) |
(56,330) |
(42,811) |
|||||||||||
Foreign exchange loss |
(2,224) |
(749) |
(9,115) |
(1,568) |
|||||||||||
Loss on extinguishment and modification of debt |
— |
(638) |
— |
(638) |
|||||||||||
Income before income tax provision and equity in loss of investees |
65,038 |
116,368 |
322,192 |
381,133 |
|||||||||||
Income tax provision |
1,239 |
26,437 |
65,914 |
100,888 |
|||||||||||
Equity in loss of investees |
273 |
103 |
637 |
103 |
|||||||||||
Net income |
$ |
63,526 |
$ |
89,828 |
$ |
255,641 |
$ |
280,142 |
|||||||
Net income per ordinary share: |
|||||||||||||||
Basic |
$ |
1.06 |
$ |
1.49 |
$ |
4.26 |
$ |
4.62 |
|||||||
Diluted |
$ |
1.03 |
$ |
1.45 |
$ |
4.17 |
$ |
4.51 |
|||||||
Weighted-average ordinary shares used in per share calculations - basic |
60,108 |
60,437 |
60,030 |
60,692 |
|||||||||||
Weighted-average ordinary shares used in per share calculations - diluted |
61,436 |
61,795 |
61,360 |
62,150 |
JAZZ PHARMACEUTICALS PLC |
|||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||
(In thousands) |
|||||||
(Unaudited) |
|||||||
September 30, |
December 31, |
||||||
ASSETS |
|||||||
Current assets: |
|||||||
Cash and cash equivalents |
$ |
252,615 |
$ |
365,963 |
|||
Investments |
200,000 |
60,000 |
|||||
Accounts receivable, net of allowances |
258,616 |
234,244 |
|||||
Inventories |
41,344 |
34,051 |
|||||
Prepaid expenses |
29,249 |
24,501 |
|||||
Other current assets |
49,120 |
29,310 |
|||||
Total current assets |
830,944 |
748,069 |
|||||
Property and equipment, net |
159,386 |
107,490 |
|||||
Intangible assets, net |
3,019,035 |
3,012,001 |
|||||
Goodwill |
941,428 |
893,810 |
|||||
Deferred tax assets, net, non-current |
23,662 |
15,060 |
|||||
Deferred financing costs |
8,149 |
9,737 |
|||||
Other non-current assets |
16,420 |
14,060 |
|||||
Total assets |
$ |
4,999,024 |
$ |
4,800,227 |
|||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|||||||
Current liabilities: |
|||||||
Accounts payable |
$ |
29,972 |
$ |
22,415 |
|||
Accrued liabilities |
179,890 |
193,268 |
|||||
Current portion of long-term debt |
36,094 |
36,094 |
|||||
Income taxes payable |
13,603 |
4,506 |
|||||
Deferred revenue |
8,618 |
1,123 |
|||||
Total current liabilities |
268,177 |
257,406 |
|||||
Deferred revenue, non-current |
18,270 |
2,601 |
|||||
Long-term debt, less current portion |
1,543,819 |
1,993,531 |
|||||
Deferred tax liability, net, non-current |
540,964 |
556,733 |
|||||
Other non-current liabilities |
158,497 |
112,617 |
|||||
Total shareholders' equity |
2,469,297 |
1,877,339 |
|||||
Total liabilities and shareholders' equity |
$ |
4,999,024 |
$ |
4,800,227 |
JAZZ PHARMACEUTICALS PLC |
|||||||
SUMMARY OF CASH FLOWS |
|||||||
(In thousands) |
|||||||
(Unaudited) |
|||||||
Nine Months Ended |
|||||||
2017 |
2016 |
||||||
Net cash provided by operating activities |
$ |
488,528 |
$ |
411,696 |
|||
Net cash used in investing activities |
(237,072) |
(1,749,296) |
|||||
Net cash provided by (used in) financing activities |
(369,127) |
713,032 |
|||||
Effect of exchange rates on cash and cash equivalents |
4,323 |
2,350 |
|||||
Net decrease in cash and cash equivalents |
$ |
(113,348) |
$ |
(622,218) |
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION |
|||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||
(Unaudited) |
|||||||||||||||
Three Months Ended |
Nine Months Ended |
||||||||||||||
2017 |
2016 |
2017 |
2016 |
||||||||||||
GAAP reported net income |
$ |
63,526 |
$ |
89,828 |
$ |
255,641 |
$ |
280,142 |
|||||||
Intangible asset amortization |
47,313 |
26,453 |
99,164 |
75,832 |
|||||||||||
Share-based compensation expense |
27,126 |
24,874 |
79,579 |
74,490 |
|||||||||||
Upfront and milestone payments |
75,000 |
15,000 |
75,000 |
23,750 |
|||||||||||
Transaction and integration related costs |
— |
10,781 |
— |
12,970 |
|||||||||||
Expenses related to certain legal proceedings and restructuring |
— |
— |
6,000 |
6,060 |
|||||||||||
Non-cash interest expense |
7,855 |
5,642 |
19,234 |
16,418 |
|||||||||||
Loss on extinguishment and modification of debt |
— |
638 |
— |
638 |
|||||||||||
Income tax effect of adjustments (1) |
(23,171) |
(12,063) |
(38,393) |
(28,775) |
|||||||||||
Non-GAAP adjusted net income |
$ |
197,649 |
$ |
161,153 |
$ |
496,225 |
$ |
461,525 |
|||||||
GAAP reported net income per diluted share |
$ |
1.03 |
$ |
1.45 |
$ |
4.17 |
$ |
4.51 |
|||||||
Non-GAAP adjusted net income per diluted share |
$ |
3.22 |
$ |
2.61 |
$ |
8.09 |
$ |
7.43 |
|||||||
Weighted-average ordinary shares used in diluted per share calculations |
61,436 |
61,795 |
61,360 |
62,150 |
(1) |
The income tax effect of the adjustments between GAAP reported and non-GAAP adjusted net income takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). |
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION |
|||||||||||||||||||||||
CERTAIN LINE ITEMS AND OTHER INFORMATION |
|||||||||||||||||||||||
(In thousands, except per share amounts and percentages) |
|||||||||||||||||||||||
(Unaudited) |
|||||||||||||||||||||||
Three Months Ended |
|||||||||||||||||||||||
September 30, 2017 |
September 30, 2016 |
||||||||||||||||||||||
GAAP |
Adjustments |
Non-GAAP |
GAAP |
Adjustments |
Non-GAAP |
||||||||||||||||||
Total revenues |
$ |
411,855 |
$ |
— |
$ |
411,855 |
$ |
374,181 |
$ |
— |
$ |
374,181 |
|||||||||||
Cost of product sales (excluding amortization of intangible assets) |
31,203 |
(1,573) |
(a) |
29,630 |
24,311 |
(1,348) |
(a) |
22,963 |
|||||||||||||||
Selling, general and administrative |
124,523 |
(20,903) |
(b) |
103,620 |
124,368 |
(29,834) |
(b) |
94,534 |
|||||||||||||||
Research and development |
47,362 |
(4,650) |
(c) |
42,712 |
47,796 |
(4,473) |
(c) |
43,323 |
|||||||||||||||
Acquired in-process research and development |
75,000 |
(75,000) |
— |
15,000 |
(15,000) |
— |
|||||||||||||||||
Intangible asset amortization |
47,313 |
(47,313) |
— |
26,453 |
(26,453) |
— |
|||||||||||||||||
Interest expense, net |
19,192 |
(7,855) |
(d) |
11,337 |
18,498 |
(5,642) |
(d) |
12,856 |
|||||||||||||||
Foreign currency loss |
2,224 |
— |
2,224 |
749 |
— |
749 |
|||||||||||||||||
Loss on extinguishment and modification of debt |
— |
— |
— |
638 |
(638) |
— |
|||||||||||||||||
Income before income tax provision and equity in loss of investees |
65,038 |
157,294 |
(e) |
222,332 |
116,368 |
83,388 |
(e) |
199,756 |
|||||||||||||||
Income tax provision |
1,239 |
23,171 |
(f) |
24,410 |
26,437 |
12,063 |
(f) |
38,500 |
|||||||||||||||
Effective tax rate (g) |
1.9 |
% |
11.0 |
% |
22.7 |
% |
19.3 |
% |
|||||||||||||||
Equity in loss of investees |
273 |
— |
273 |
103 |
— |
103 |
|||||||||||||||||
Net income |
$ |
63,526 |
$ |
134,123 |
(h) |
$ |
197,649 |
$ |
89,828 |
$ |
71,325 |
(h) |
$ |
161,153 |
|||||||||
Net income per diluted share |
$ |
1.03 |
$ |
3.22 |
$ |
1.45 |
$ |
2.61 |
JAZZ PHARMACEUTICALS PLC |
|||||||||||||||||||||||
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION |
|||||||||||||||||||||||
CERTAIN LINE ITEMS AND OTHER INFORMATION |
|||||||||||||||||||||||
(In thousands, except per share amounts and percentages) |
|||||||||||||||||||||||
(Unaudited) |
|||||||||||||||||||||||
Nine Months Ended |
|||||||||||||||||||||||
September 30, 2017 |
September 30, 2016 |
||||||||||||||||||||||
GAAP |
Adjustments |
Non-GAAP |
GAAP |
Adjustments |
Non-GAAP |
||||||||||||||||||
Total revenues |
$ |
1,182,294 |
$ |
— |
$ |
1,182,294 |
$ |
1,091,352 |
$ |
— |
$ |
1,091,352 |
|||||||||||
Cost of product sales (excluding amortization of intangible assets) |
84,940 |
(4,346) |
(i) |
80,594 |
71,730 |
(3,110) |
(i) |
68,620 |
|||||||||||||||
Selling, general and administrative |
401,106 |
(67,582) |
(j) |
333,524 |
375,751 |
(79,118) |
(j) |
296,633 |
|||||||||||||||
Research and development |
132,447 |
(13,651) |
(k) |
118,796 |
118,139 |
(11,292) |
(k) |
106,847 |
|||||||||||||||
Acquired in-process research and development |
77,000 |
(75,000) |
2,000 |
23,750 |
(23,750) |
— |
|||||||||||||||||
Intangible asset amortization |
99,164 |
(99,164) |
— |
75,832 |
(75,832) |
— |
|||||||||||||||||
Interest expense, net |
56,330 |
(19,234) |
(d) |
37,096 |
42,811 |
(16,418) |
(d) |
26,393 |
|||||||||||||||
Foreign currency loss |
9,115 |
— |
9,115 |
1,568 |
— |
1,568 |
|||||||||||||||||
Loss on extinguishment and modification of debt |
— |
— |
— |
638 |
(638) |
— |
|||||||||||||||||
Income before income tax provision and equity in loss of investees |
322,192 |
278,977 |
(l) |
601,169 |
381,133 |
210,158 |
(l) |
591,291 |
|||||||||||||||
Income tax provision |
65,914 |
38,393 |
(f) |
104,307 |
100,888 |
28,775 |
(f) |
129,663 |
|||||||||||||||
Effective tax rate (g) |
20.5 |
% |
17.4 |
% |
26.5 |
% |
21.9 |
% |
|||||||||||||||
Equity in loss of investees |
637 |
— |
637 |
103 |
— |
103 |
|||||||||||||||||
Net income |
$ |
255,641 |
$ |
240,584 |
(m) |
$ |
496,225 |
$ |
280,142 |
$ |
181,383 |
(m) |
$ |
461,525 |
|||||||||
Net income per diluted share |
$ |
4.17 |
$ |
8.09 |
$ |
4.51 |
$ |
7.43 |
Explanation of Adjustments and Certain Line Items (in thousands): |
|
(a) |
Share-based compensation expense of $1,573 and $1,307 and transaction and integration related costs of $0 and $41 for the three months ended September 30, 2017 and 2016, respectively. |
(b) |
Share-based compensation expense of $20,903 and $19,511 and transaction and integration related costs of $0 and $10,323 for the three months ended September 30, 2017 and 2016, respectively. |
(c) |
Share-based compensation expense of $4,650 and $4,056 and transaction and integration related costs of $0 and $417 for the three months ended September 30, 2017 and 2016, respectively. |
(d) |
Non-cash interest expense associated with debt discount and debt issuance costs for the respective three- and nine-month periods. |
(e) |
Sum of adjustments (a) through (d) plus the adjustments for acquired in-process research and development, intangible asset amortization and loss on extinguishment and modification of debt for the respective three-month period. |
(f) |
Income tax effect of the adjustments between GAAP reported and non-GAAP adjusted net income takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s) for the respective three- and nine-month periods. |
(g) |
Income tax provision divided by income before income tax provision and equity in loss of investees for the respective three- and nine-month periods. |
(h) |
Net of adjustments (e) and (f) for the respective three-month period. |
(i) |
Share-based compensation expense of $4,346 and $2,959, expenses related to certain legal proceedings and restructuring of $0 and $110 and transaction and integration related costs of $0 and $41 for the nine months ended September 30, 2017 and 2016, respectively. |
(j) |
Share-based compensation expense of $61,582 and $60,664, expenses related to certain legal proceedings and restructuring of $6,000 and $5,950 and transaction and integration related costs of $0 and $12,504 for the nine months ended September 30, 2017 and 2016, respectively. |
(k) |
Share-based compensation expense of $13,651 and $10,867 and transaction and integration related costs of $0 and $425 for the nine months ended September 30, 2017 and 2016, respectively. |
(l) |
Sum of adjustments (i), (j), (k) and (d) plus the adjustments for acquired in-process research and development, intangible asset amortization and loss on extinguishment and modification of debt, as applicable, for the respective nine-month period. |
(m) |
Net of adjustments (l) and (f) for the respective nine-month period. |
JAZZ PHARMACEUTICALS PLC |
|
RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2017 NET INCOME GUIDANCE |
|
(In millions, except per share amounts) |
|
(Unaudited) |
|
GAAP net income |
$325 - $385 |
Intangible asset amortization |
130 - 165 |
Share-based compensation expense |
95 - 110 |
Upfront and milestone payments |
75 |
Expenses related to certain legal proceedings and restructuring |
6 |
Non-cash interest expense |
30 - 35 |
Income tax effect of adjustments |
(50) - (60) |
Non-GAAP adjusted net income |
$655 - $685 |
GAAP net income per diluted share |
$5.30-$6.30 |
Non-GAAP adjusted net income per diluted share |
$10.70-$11.20 |
Weighted-average ordinary shares used in per share calculations |
61 |
View original content with multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2017-financial-results-300551288.html
SOURCE
Investors: Kathee Littrell, Vice President, Investor Relations, Jazz Pharmaceuticals plc, Ireland, +353 1 634 7887, U.S., +1 650 496 2717; Media: Jacqueline Kirby, Vice President, Corporate Affairs & Government Relations, Jazz Pharmaceuticals plc, Ireland, +353 1 697 2141, U.S., +1 215 867 4910